EUVIMEDEUVIMED entdecken
Crossref

P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors

Miho Kure, Hiroshi Tazawa, Koji Demiya, Hiroya Kondo, Yusuke Mochizuki, Tadashi Komatsubara, Aki Yoshida, Koji Uotani, Joe Hasei, Tomohiro Fujiwara, Toshiyuki Kunisada, Yasuo Urata und 3 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.17924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Miho Kure und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Osteosarcoma, Oncolytic Virotherapy, Tumor Suppressor Protein p53, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaOncolytic VirotherapyTumor Suppressor Protein p53Programmed Cell Death 1 ReceptorBone NeoplasmsImmune Checkpoint InhibitorsAnimalsMiceCell Line, TumorOncolytic VirusesAdenoviridaeHumansB7-H1 Antigen

Stichwörter der Autor:innen

OsteosarcomaP53PD1immunogenic cell deathoncolytic adenovirus

Substanzen

Tumor Suppressor Protein p53Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsB7-H1 AntigenTrp53 protein, mouse

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; htazawa@md.okayama-u.ac.jp.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Sports Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Oncolys BioPharma, Inc., Tokyo, Japan.

Zitieren

APA

Kure, M., Tazawa, H., Demiya, K., Kondo, H., Mochizuki, Y., Komatsubara, T., Yoshida, A., Uotani, K., Hasei, J., Fujiwara, T., Kunisada, T., Urata, Y., Kagawa, S., Ozaki, T., & Fujiwara, T. (2026). P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. Anticancer Research. https://doi.org/10.21873/anticanres.17924

Vancouver

Kure M, Tazawa H, Demiya K, Kondo H, Mochizuki Y, Komatsubara T, et al. P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. Anticancer Research. 2026. doi:10.21873/anticanres.17924

BibTeX
@article{Kure2026,
  author = {Kure, Miho and Tazawa, Hiroshi and Demiya, Koji and Kondo, Hiroya and Mochizuki, Yusuke and Komatsubara, Tadashi and Yoshida, Aki and Uotani, Koji and Hasei, Joe and Fujiwara, Tomohiro and Kunisada, Toshiyuki and Urata, Yasuo and Kagawa, Shunsuke and Ozaki, Toshifumi and Fujiwara, Toshiyoshi},
  title = {P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.17924}
}
Kostenlos starten →